|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
|
TUESDAY, DECEMBER 10, 2019 |
|
8:00 am - 7:00 pm
|
REGISTRATION
- Main Lobby |
|
|
|
Pre-registered attendees can obtain materials. Those who have not yet registered may do so.
|
|
|
| 11:45 am - 1:45 pm |
WORKSHOPS |
|
| |
Molecular Biology in Breast Oncology - Hemisfair Ballroom - 3rd Level
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Antibody-drug conjugates in cancer: Principles for synthesis and preclinical development
Gail Lewis Phillips
Genentech, Inc.
South San Francisco, CA
Defining a cancer dependency map
William C. Hahn, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Approaches to targeting the anti-apoptotic machinery in breast cancer
Geoffrey Lindeman, MBBS, FRACP, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA
Novel target discovery by longitudinal deep spatial & molecular analysis of breast cancers
Joe Gray, PhD
Oregon Health & Science University
Portland, OR
|
|
| |
|
|
| |
Developing Novel Therapeutics in the Metastatic Setting - Stars at Night Ballroom 3&4 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Window versus neoadjuvant trial - choose wisely
Alastair M. Thompson, BSc (Hons), MB ChB, FRCSEd
Baylor College of Medicine
Houston, TX
Therapeutic development in the era of precision medicine: Paradigm shift from maximum tolerated dose (MTD) to optimal biological dose (OBD)
Aditya Bardia, MD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Design and analysis of window and neoadjuvant trials
Meredith Regan, ScD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
How to talk to patients about participating in clinical trials
Patricia Spears, BSc
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC
|
|
| |
|
|
| 1:45 pm - 2:00 pm |
BREAK
|
|
| |
|
|
| 2:00 pm - 7:00 pm
|
EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1, 2, 3&4 and Hemisfair Ballroom - 3rd Level
Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees
with a better understanding of the background leading up to talks they
will hear in the succeeding days, and some of the techniques that will
be used. These presentations should also provide researchers with ideas
and techniques to be considered for their own studies.
|
|
|
|
|
|
| 2:00 pm - 3:30 pm
|
Immunotherapy for Triple-Negative Breast Cancer - Stars at Night Ballroom 1 - 3rd Level
Moderator: Sylvia Adams, MD
NYU Langone Health
New York, NY
The emerging role of immunotherapy for the treatment of early and advanced breast cancer
Rita Nanda, MD
University of Chicago
Chicago, IL
Detecting and managing immunotherapy-related toxicities wisely
Peter Schmid, MD, PhD
Barts Cancer Institute
London, UNITED KINGDOM
Assessment of PD-L1 in breast cancer to predict response to immunotherapy
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT
SABCS and the American Society for Radiation Oncology (ASTRO) present Evolving Opportunities to Personalize Radiation Decisions - Stars at Night Ballroom 2 - 3rd Level
Moderator: Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI
Guiding decisions to omit radiotherapy after breast-conserving surgery for DCIS. Can genomic biomarkers help?
Eileen Rakovitch, MD, MSc, FRCPC
Sunnybrook Health Sciences Centre
Toronto, CANADA
Evolving opportunities to personalize radiation decisions - Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer
Corey Speers, MD, PhD
University of Michigan
Ann Arbor, MI
Guiding selection of RT approach after lumpectomy
Simona Shaitelman, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Breast Cancer Prevention – Stars at Night Ballroom 3&4 - 3rd Level
Moderator:
Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them
Maxine S. Jochelson, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Sooner or later:
considering risk over time, and implications for management
Seema A. Khan, MD
Northwestern University
Chicago, IL
Low dose tamoxifen and other approaches to improve chemoprevention uptake
Andrea De Censi, MD
E.O. Ospedali Galliera
Genova, ITALY
Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations ‐ Hemisfair Ballroom - 3rd Level
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Adaptive resistance to hormonal therapy
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX
Single cell transcriptomics reveals multi-step adaptations to endocrine therapy
Luca Magnani, PhD
Imperial College London
London, UNITED KINGDOM
The genomic landscape of endocrine-resistant metastatic breast cancer
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
|
|
|
|
|
|
| 3:45 pm - 5:15 pm
|
SABCS with the Society of Surgical Oncology present Multidisciplinary Approaches to Optimizing Surgical Therapy for Hormone Receptor Positive Breast Cancer – Stars at Night Ballroom 1 - 3rd Level
Moderator:
Armando Giuliano, MD
Cedars-Sinai Medical Center
Los Angeles, CA
Neoadjuvant therapy for hormone receptor positive breast cancer: Advances and challenges
Otto Metzger, MD
Dana-Farber Cancer Institute
Boston, MA
Axillary management for hormone receptor positive breast cancer PRIOR to systemic therapy
Melissa L. Pilewskie, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Surgical considerations AFTER preoperative therapy for hormone receptor positive breast cancer
Tari Ann King, MD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA
Implementation of Genetic Testing in Breast Cancer Patients – Stars at Night Ballroom 2 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Who should have germline testing for hereditary breast cancer?
Nadine Tung, MD
Beth Israel Deaconess Medical Center
Boston, MA
Alternative practical models for genetic services in the era of increased demand
Banu Arun, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Breast cancer genetic testing: moving from cancer risk assessment to therapeutic biomarker
Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, SPAIN
Conversations on Tough Topics Surrounding Cancer Care – Stars at Night Ballroom 3&4 - 3rd Level
Moderator:
Susan Rafte
Community Advocate, Baylor College of Medicine Breast Center
Houston, TX
Progression of disease and end of life: How to break bad news
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
The toll on healthcare providers
Sharon H. Giordano, MD, MPH, FASCO
University of Texas MD Anderson Cancer Center
Houston, TX
The financial costs and burden of breast cancer care
Rachel A. Greenup, MD, MPH
Duke Cancer Institute
Durham, NC
Panel Discussion
Thelma P. Brown
University of Alabama at Birmingham
Birmingham, AL
Katherine O'Brien
Metastatic Breast Cancer Network
New York, NY
Endocrine Therapy in 2020 - Hemisfair Ballroom - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Adjuvant endocrine therapy in 2020: It's complicated
Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, ITALY
Future directions in endocrine therapy for advanced HER+/HER2- breast cancer
Erica L. Mayer, MD, MPH
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Everything comes at a price - Toxicity, cost and adherence to endocrine therapy
Dawn Hershman, MD
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY
|
|
|
|
|
|
| 5:30 pm - 7:00 pm
|
Discussing Risk in the Context of GEP Testing - Stars at Night Ballroom 1 - 3rd Level
Moderator:
Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM
Discussing risk & uncertainty with patients in the context of GEP testing
Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM
Communicating risk information, talking by numbers
Valerie Ann Jenkins, DPhil, BSc
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM
Breast Cell Fate Control and Plasticity – Stars at Night Ballroom 2 - 3rd Level
Moderator:
Yi Li, PhD
Baylor College of Medicine
Houston, TX
Cellular plasticity, fate, potential and lineage commitment of mammary gland stem cells
Cedric Blanpain, MD, PhD
Universite Libre de Bruxelles
Bruxelles, BELGIUM
Understanding breast cancer using a developmental perspective
Geoffrey Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA
Cell fate plasticity during breast cancer development - where is the translational utility?
Christina Scheel, MD
Helmholtz Center Munich
Institute of Stem Cell Research
Neuherberg, GERMANY
Tailoring Adjuvant Therapies Based on Neoadjuvant Response - Stars at Night Ballroom 3&4 - 3rd Level
Moderator:
Charles E. Geyer, MD
Virginia Commonwealth University
Massey Cancer Center
Richmond, VA
The biology and plasticity of residual disease after neoadjuvant therapy
Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC
Neoadjuvant systemic treatment (NST): Tailoring response by subtype
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
Local treatments in patients who achieve pathologic complete response
Julia White, MD
The Ohio State University
Columbus, OH
Targeted Treatment Beyond PARP1 Inhibition - Hemisfair Ballroom - 3rd Level
Moderator: Alexander Bishop, DPhil
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX
Clinical indications of PARP1 inhibitors and other targets
Melinda L. Telli, MD
Stanford University Medical Center
Stanford, CA
Targeted DNA repair in cancer and new NUDT5 inhibitors to block hormone signalling to target breast cancer
Thomas Helleday, PhD
University of Sheffield
Sheffield, UNITED KINGDOM
Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments
Violeta Serra, PhD
Vall d'Hebron Institute of Oncology
Barcelona, SPAIN
|
|
| |
|
|
| 7:30 pm - 10:00 pm |
OPEN SATELLITE EVENT presented by PVI, Peer View Institute for Medical Education - Marriott Rivercenter
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
|
|
|
|